Vyndaqel (tafamidis)

pCPA File Number: 21922

Negotiation Status:

Under consideration for negotiation

Indication(s):

Cardiomyopathy due to transthyretin-mediated amyloidosis

Sponsor/Manufacturer:

Pfizer Canada ULC

CADTH Project Number:

SF0722

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable